GlassScriptPhysician profile
James G Towery
NPI 1497966287
$6,388.34
in general payments reported to CMS, 2019-2025
21 companies · $505 in 2025
The $505 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $162 · 2021: $201 · 2022: $4,087 · 2023: $615 · 2024: $245 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,043 · Travel and Lodging: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,042.63 |
| Travel and Lodging | $323.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,019.59 | 2022-2025 | Selectsecure, Cobalt Dr Mri Surescan, In.Pact Admiral |
| Novartis Pharmaceuticals Corporation | $902.22 | 2019-2025 | |
| Pfizer INC. | $251.59 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $237.43 | 2019-2023 | Xarelto |
| Abbott Laboratories | $217.01 | 2019-2023 | Assurity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.15 | 2020-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $109.85 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.07 | 2020-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $61.06 | 2022-2024 | Opsumit, Uptravi |
| Novo Nordisk INC | $51.62 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Impulse Dynamics (USA) INC. | $49.89 | 2022-2023 | Optimizer |
| Astellas Pharma US INC | $46.56 | 2019-2020 | |
| Esperion Therapeutics, INC. | $39.30 | 2020-2024 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $39.13 | 2019-2021 | |
| Biosense Webster, INC. | $37.73 | 2025 | Carto 3 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $35.53 | 2023-2024 | Kengreal |
| Philips North America LLC | $33.60 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $17.29 | 2024 | |
| Convatec INC. | $16.63 | 2019 | |
| Amgen INC. | $15.09 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Towery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.